113 related articles for article (PubMed ID: 2680799)
1. Prediction of the presence of ovarian cancer at surgery by an immunochemical panel: CA 125 and copper-to-zinc ratio.
Gal D; Lischinsky S; Friedman M; Zinder O
Gynecol Oncol; 1989 Nov; 35(2):246-50. PubMed ID: 2680799
[TBL] [Abstract][Full Text] [Related]
2. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
3. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
4. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
6. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
[TBL] [Abstract][Full Text] [Related]
7. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy.
Lightman A; Brandes JM; Binur N; Drugan A; Zinder O
Clin Chem; 1986 Jan; 32(1 Pt 1):101-3. PubMed ID: 3940688
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas.
Barrenetxea G; Martin-Mateos M; Barzazan MJ; Montoya F; Matia JC; Rodriguez-Escudero FJ
Eur J Gynaecol Oncol; 1990; 11(5):369-74. PubMed ID: 2097153
[TBL] [Abstract][Full Text] [Related]
9. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
10. Value of serum 125Ca levels: does the result preclude second look?
Potter ME; Moradi M; To AC; Hatch KD; Shingleton HM
Gynecol Oncol; 1989 May; 33(2):201-3. PubMed ID: 2703182
[TBL] [Abstract][Full Text] [Related]
11. Does intraperitoneal CA-125 reflect disease status?
Buller RE; Manetta A; Bloss JD; DiSaia PJ; Berman ML
Gynecol Oncol; 1991 Jan; 40(1):66-9. PubMed ID: 1989917
[TBL] [Abstract][Full Text] [Related]
12. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
13. Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125.
Mogensen O; Mogensen B; Jakobsen A
Cancer; 1989 Nov; 64(9):1867-71. PubMed ID: 2477138
[TBL] [Abstract][Full Text] [Related]
14. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Rose PG; Terrien JM; Baker S
J Surg Oncol; 1994 Jul; 56(3):168-71. PubMed ID: 8028348
[TBL] [Abstract][Full Text] [Related]
15. [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].
Meden H; Rath W; Ohlmeyer D
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):101-5. PubMed ID: 2180783
[TBL] [Abstract][Full Text] [Related]
16. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
[TBL] [Abstract][Full Text] [Related]
18. Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer.
Aravantinos D; Michalas S; Papazefkos V; Christoforaki M; Stypsaneli A; Vlachos G; Athanasiadis P
Eur J Obstet Gynecol Reprod Biol; 1990 Dec; 37(3):265-70. PubMed ID: 2227069
[TBL] [Abstract][Full Text] [Related]
19. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
Jäger W; Adam R; Wildt L; Lang N
Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
[TBL] [Abstract][Full Text] [Related]
20. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
